Axsome Therapeutics reports preliminary net product revenue for Q4 and full-year 2025

Axsome Therapeutics said it is providing preliminary fourth-quarter and full-year 2025 net product revenue and included customary forward-looking statements outlining risks and uncertainties.

Axsome Therapeutics said it is providing preliminary fourth quarter and full-year 2025 net product revenue in a press release dated January 12, 2026. The company included customary forward-looking statements that describe possible risks and uncertainties. The release names the company's marketed products and several potential factors that could affect future results. The company also notes these forward-looking statements are made as of the release date and may not be updated. Key details: - The company provided preliminary net product revenue figures for the fourth quarter and full year 2025. - The press release includes forward-looking statements and lists example words used to identify them, such as "expects," "anticipates," "may," and similar terms. - The forward-looking language identifies risks and uncertainties, including the commercial success of SUNOSI, AUVELITY, and SYMBRAVO; efforts to obtain additional indications for solriamfetol and AXS-05; payer coverage; clinical trial timing, enrollment and funding; regulatory approvals; intellectual property matters; and capital requirements. - The release states that unforeseen circumstances, including geopolitical events, pandemics, general economic conditions, and regulatory developments, could affect results. - The company says the forward-looking statements are made as of the press release date and that it undertakes no obligation to publicly update them. Summary: Axsome's announcement provides an early report of net product revenue for Q4 and the full year 2025 while reiterating a range of operational and regulatory uncertainties that could affect outcomes. Undetermined at this time.